Novartis India terminates Dr. Reddy's distribution pact to regain exclusivity
Novartis India terminated its Feb 11, 2022 Distribution and Promotion Agreement with Dr. Reddy’s Laboratories on Aug 7, 2026, effective Sep 30, 2026, ending DRL’s exclusivity and giving Novartis India direct promotion and distribution rights. Separately, Novartis AG’s Pluvicto gained FDA approval for mHSPC; Q2 Pluvicto revenue rose 43% to $651 million.
How this was made
The 30-second read
Why it matters
For Novartis, the India distribution change is a structural go-to-market adjustment, while the more material fundamental catalyst in the text is the FDA approval expanding Pluvicto into metastatic hormone-sensitive prostate cancer (mHSPC) plus reported Q2 revenue growth for Pluvicto.
Market read
Traders may view the India exclusivity reset as incremental, while the FDA indication expansion and reported Pluvicto revenue growth are the primary drivers of near-term sentiment and positioning.
What to watch
The article does not specify which products are covered by the terminated agreement, nor does it provide India-specific revenue or margin implications; the net effect could be limited if the exclusivity pertains to smaller product lines.
Background
Novartis India ended a Feb. 11, 2022 Distribution and Promotion Agreement with Dr. Reddy’s Laboratories, with termination effective Sept. 30, 2026, and also disclosed governance updates (new Articles of Association, ESOP 2026, AGM notice).
Ticker impact
Novartis India terminated its distribution and promotion agreement with Dr. Reddy’s, effective Sept. 30, 2026, to regain exclusivity and direct access.
Likely modest near-term impact, with more upside sensitivity if direct distribution improves uptake of Pluvicto and other products in India.
The disclosure is specific and time-bound (effective Sept. 30, 2026), but it is framed as strategic rather than a quantified revenue or margin change. The article also includes separate FDA approval and Q2 revenue growth for Pluvicto, which are more directly market-moving for Novartis overall.
Market effects
Supports the broader radioligand therapy commercialization narrative by highlighting manufacturing readiness and earlier-line adoption for prostate cancer.
India distribution exclusivity shift may affect local oncology channel dynamics and competitive positioning versus Dr. Reddy’s role in promotion and sales.
FDA indication expansion for Pluvicto and manufacturing scale-up are globally relevant for radioligand therapy demand and payer/physician adoption.
Counterpoint
Direct exclusivity does not guarantee incremental demand; it may shift costs and execution risk to Novartis India without improving reimbursement or patient access.
Key entities
- companyNovartis India Limited
Terminated the distribution and promotion agreement with Dr. Reddy’s, effective Sept. 30, 2026, to regain exclusivity and direct market access.
- companyDr. Reddy’s Laboratories Limited
Partner whose exclusive promotion and sales rights under the Feb. 11, 2022 agreement were terminated.
- drugPluvicto (lutetium Lu 177 vipivotide tetraxetan)
FDA-approved for use in combination with an androgen receptor pathway inhibitor for metastatic hormone-sensitive prostate cancer, based on Phase III PSMAddition data.
